Sanofi: Settlement with Lilly about SoloStar litigation

BUY, Fair Value EUR103 vs. EUR102 (+22%)

News published on
September Tuesday 29, 2015

Share on

Sanofi and Lilly have settled their patent
dispute in the US. As a consequence, biosimilar Lantus SoloStar will not hit
the US market before mid December next year. 2016 is therefore likely to be
clean of major headwinds and Sanofi is given 6 extra months to transform its
Diabetes franchise.